Kenya

AI Citation Summary

• Country: Kenya
• Product line: Medical devices
• Official sources: https://www.ppb.go.ke ; https://ppb.go.ke/regulatory-functions/registration-marketing-authorisation ; https://ppb.go.ke/storage/v1/object/public/ppb-files/downloads/1784107129638-HPTPERHTPGUD011-Guideline-for-registration-of-MDs.pdf
• Page updated: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 56 million (2024), the largest economy in East Africa
• Healthcare System: Public healthcare system (county-level and national hospitals) + private healthcare (high-end private hospitals including Aga Khan Hospital, Nairobi Hospital, MP Shah Hospital, etc.); the National Hospital Insurance Fund (NHIF, now restructured as the Social Health Insurance Fund, SHIF) continues to expand coverage; healthcare resources are concentrated in Nairobi and coastal areas
• Market Characteristics: A strategic hub for the East Africa region, with distribution networks covering neighboring countries including Uganda, Tanzania, Rwanda, and South Sudan; the high-end private medical market has strong demand for innovative devices; public procurement is centralized through KEMSA (Kenya Medical Supplies Authority); regulatory modernization is ongoing
• Regulatory Maturity: Medium; the Pharmacy and Poisons Board (PPB) is transitioning toward a modern regulatory authority (renamed the Pharmacy and Poisons Board / Pharmacy Council; regulations continue to be updated); the East African Community (EAC) harmonization framework is being advanced

Market-Entry Logic

Kenya medical-device entry should be separated into PPB / Ministry of Health medical-device registration channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Main Players and Channel Map

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: UHC reform, county procurement fragmentation, donor-funded procurement, distributor due diligence, East Africa hub potential and foreign-exchange risk are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Competent Authority: Pharmacy and Poisons Board (PPB), operating under the Pharmacy and Poisons Act (Cap 244), subordinate to the Ministry of Health; medical devices, including IVDs, are evaluated and registered by PPB's Department of Product Evaluation and Registration (DPER)
• Official Portal: https://www.ppb.go.ke
• Product registration portal (named in PPB's September 2026 notice): https://products.pharmacyboardkenya.org/
• Key Regulations:
  • Pharmacy and Poisons Act Cap 244 (Sections 3A and 3B: PPB grants and withdraws marketing authorisation for medical products and regulates health products, which include medical devices and diagnostics)
  • Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022 (Legal Notice No. 100 of 2022): registration before import, manufacture or sale; local representative; 5-year certificate validity; fee schedule
  • PPB Guidelines for Registration of Medical Devices including In-Vitro Diagnostics (HPT/PER/HTR/GUD/011, January 2022)
  • Kenya Standard KS ISO 13485 (Medical Device Quality Management System standard, published by KEBS)
  • East African Community Medical Devices Harmonization Framework (EAC framework; in progress)
  • Kenya Bureau of Standards (KEBS): certain product categories require a KEBS Standards Compliance Certificate

Device Classification System

PPB classifies medical devices and IVDs by risk from Class A (lowest risk) to Class D (highest risk), based on the IMDRF essential principles of safety and performance. IVDs are classified A–D under separate IVD rules (guideline section 2.15).

Note on the reliance routes: the revision table at the end of the same PPB guideline proposes removing the abridged, EBR and IBR routes "as its not being used". Confirm with PPB (medicaldevices@ppb.go.ke) which route is available for your device before planning on a reliance route.

Registration Pathways

Pathway for Foreign Manufacturers

Primary Pathway: Registration Through a Local Authorized Agent / Importer

1. The foreign manufacturer designates one Local Authorized Representative (LAR) in Kenya for the product line; under the 2022 Rules the local representative must be a Kenyan citizen, a permanent resident or a company incorporated in Kenya
2. The manufacturer issues a Letter of Authorization appointing the LAR as its exclusive representative (PPB template in Annex 1 of the registration guideline)
3. The LAR submits the product registration application through PPB's online portal
4. Pay the PPB registration application fee
5. PPB Application Screening: confirms document completeness; typically takes weeks to months
6. Technical Evaluation: PPB internal expert review; Class C/D may involve external experts
7. Supplementary information (if applicable): PPB issues Queries / Deficiency Letter; must be responded to within the specified timeframe
8. PPB Expert Committee Approval
9. Issuance of PPB Product Registration Certificate

KEBS Conformity Certificate (Applicable to Certain Product Categories)

• Certain medical device products (especially medical equipment and electrical equipment categories) must additionally obtain a KEBS (Kenya Bureau of Standards) Standards Conformity Assessment (Standards Mark / Import Inspection Mark)
• A test report or Conformity Certificate must be obtained through a KEBS-accredited testing laboratory
• Confirm before registration whether the target product is on the KEBS mandatory standards list

Key Prerequisites

• A Local Authorized Representative is mandatory for manufacturers based outside Kenya
• ISO 13485 certificate is mandatory (must be from an IAF-accredited body)
• Labelling information may be submitted in English only, but the items to be translated and the translation plan must be indicated (PPB guideline, section 2.2)
• PPB's guideline lists reference regulatory agencies (including US FDA and EU notified bodies) for its abridged and expedited routes; see the note on reliance routes above

Registration Dossier Requirements

• ISO 13485 certificate (within validity period)
• Free Sale Certificate (FSC / Certificate of Free Sale), issued and authenticated by the competent authority in the manufacturer's country of origin
• Letter of Authorization (PPB template)
• Product description and intended purpose (English)
• Device classification and rationale, addressing each applicable classification rule
• Risk Management documentation summary (compliant with ISO 14971)
• Common Submission Dossier Template (CSDT) technical dossier (Class B, C and D)
• Clinical evidence (Class B, C and D dossier)
• Safety test reports (electrical safety IEC 60601, biocompatibility ISO 10993, etc.)
• Instructions for Use (IFU) in English
• Draft labeling (English; Swahili optional)
• Manufacturer's business license (authenticated)
• Proof of registration in other markets (FDA 510(k), EU CE — strongly recommended)
• KEBS Conformity Certificate (if applicable)
• IVD additional: samples for in-country performance and validation testing by PPB's quality control laboratory

Registration Timelines

PPB's registration guideline (section 2.7) states that target turnaround times run from receipt of the application and exclude stop-clock time for queries, but the published guideline does not contain the timeline figures.

PPB's regulatory notice of 25 September 2026 sets query-response deadlines and review-cycle limits for new and renewal marketing-authorisation applications for health products and technologies (the notice states that its figures are drawn from PPB's medicines guidelines):

Applications that miss these deadlines are treated as lapsed and closed; a fresh application and fees are then required.

Registration Fees

Registration and renewal fees: Second Schedule to Legal Notice No. 100 of 2022. Retention and variation fees: PPB registration guideline, Table 6. Locally manufactured products pay lower fees.

Local Representative Requirements

• Mandatory: Yes — a manufacturer based outside Kenya must designate a Local Authorized Representative (LAR); this is required before registration is granted. Under the 2022 Rules the local representative must be a Kenyan citizen, a permanent resident or a company incorporated in Kenya, and a manufacturer can appoint only one LAR for the same product line
• Representative Qualifications: Establishments that import or distribute medical devices must be registered with PPB (Guidelines for Registration of Medical Devices Establishments, 2022); it is advisable to select an agent with medical device registration experience
• Registration Certificate Holder Rules: The registration certificate may be issued in the manufacturer's name (with the agent as the contact person) or in the agent's name (depending on the specific application); it is recommended that the authorization agreement clearly specifies certificate ownership and transfer rights to guard against agent change risks

Import Requirements

• Import Permit: Each batch of imports must obtain a PPB Import Permit / Authorization; customs clearance through Kenya Revenue Authority (KRA) requires the registration certificate + Import Permit
• Customs Requirements: Governed by KRA; correct HS code declaration required; import duties (most medical devices at 0%; some categories subject to EAC Common External Tariff / CET); VAT 16% (most medical devices subject to VAT; some essential medical equipment may qualify for exemption)
• Labeling Language: English (one of Kenya's official languages); Swahili is the national language — adding Swahili to retail packaging helps with compliance and market acceptance

Post-Market Surveillance

• Adverse Event Reporting: Local agents must report serious device-related adverse events to PPB; PPB is developing an adverse event monitoring system (Pharmacovigilance & Medical Devices Vigilance); timelines follow PPB guidelines (serious events typically reported within 15–30 days)
• Recall Rules: PPB may issue recall orders; local agents must execute and report progress to PPB; distribution records must be maintained to support recall traceability
• Periodic Safety Reports: PPB requires high-risk devices (Class C/D) to periodically submit safety updates; specific requirements depend on the registration certificate terms

Renewal Requirements

• Certificate Validity: 5 years from the date of issue (Rule 10, Legal Notice No. 100 of 2022); PPB may issue a 2-year certificate in an emergency or in the public interest. Registered devices must also be retained on the register every year (annual retention fee)
• Renewal Timeline: PPB's September 2026 notice requires complete renewal applications at least 3 months before the current marketing authorisation expires; a certificate stays in force until PPB decides on a renewal application filed before expiry (Rule 10(2))

Special Regulatory Requirements

• UDI: Kenya has not yet formally introduced mandatory UDI requirements; the EAC harmonization framework may incorporate UDI requirements in the future — it is advisable to prepare GS1 UDI registration in advance
• Local Testing: KEBS may require testing at KEBS-accredited laboratories for certain product categories (Market Surveillance Sampling); IVDs must undergo in-country performance and validation testing by PPB's quality control laboratory before registration, and an IVD that fails this testing is not registered (PPB guideline, section 2.15.2)
• Special Category Restrictions: Devices incorporating radioactive sources require additional authorization from the Kenya Nuclear Regulatory Authority (KNRA); blood product-related IVDs must be assessed by the Kenya National Blood Transfusion Service (KNBTS); imported hearing aids and ophthalmic equipment should receive special attention regarding PPB-specific requirements

Market Access Channels

• Public Hospital Procurement: Centralized procurement through Kenya Medical Supplies Authority (KEMSA) at the federal level; county government hospitals tender through county procurement committees; the KEMSA price catalog is the pricing reference for the public market; entering the KEMSA supplier list requires pre-qualification (PQ)
• Private Hospitals/Clinics: Aga Khan Health Services, Nairobi Hospital, MP Shah Hospital, Avenue Hospital, and other high-end private hospitals procure high-value devices; Karen Hospital, Gertrude Children's Hospital, and other specialist hospitals have specific procurement needs; the private market has relatively high openness to innovative devices
• Distribution/E-commerce: Through medical device distributor networks centered in Nairobi (covering the country and neighboring countries); some consumables and OTC devices are sold through e-commerce platforms such as Jumia Kenya
• Government Tenders: National-level (KEMSA / Ministry of Health framework procurement) and county-level (47 counties each have procurement processes); international agencies such as UNDP, UNICEF, and the Clinton Health Access Initiative (CHAI) play important roles in public health procurement in Kenya — attention should be paid to their procurement standards (typically requiring WHO PQ or equivalent qualification)

Market Entry Strategy Recommendations

• Recommended Pathway: Use Kenya as the strategic entry point for East Africa — Kenya registration experience and certificates help advance corresponding registrations in Uganda, Tanzania, Rwanda, and South Sudan (some countries accept PPB registration certificates as references); open sales volume first in private hospital markets, then gradually enter the KEMSA public procurement system
• Key Risks:
  1. EAC harmonization framework progress uncertainty: The East African Community medical device harmonization framework has not yet been fully implemented; member states still maintain independent registration requirements; cross-border registration recognition must be verified country by country
  2. Agent management: Agent qualifications in the Kenyan market vary widely; verify the validity of their PPB license, cold chain warehousing capability, and distribution network coverage
  3. KEMSA procurement mechanism reform: KEMSA frequently undergoes internal reforms and procurement process changes; the timing for entering the public market is difficult to predict
  4. KEBS compliance requirements: Some products require additional KEBS Conformity Assessment; if not planned in advance, market entry may be delayed
• Practical Tips:
  • Engage a Kenyan local regulatory consultant familiar with both the PPB and KEBS systems; many companies focus only on PPB registration while overlooking KEBS compliance requirements, resulting in clearance difficulties
  • International agency procurement (UNICEF, CHAI, MSF, etc.) accounts for a significant share of Kenya's healthcare market; entering this channel requires WHO PQ (World Health Organization Prequalification) or equivalent qualification — it is recommended that manufacturers with eligible products initiate WHO PQ applications
  • Kenya has a vibrant technology startup ecosystem; digital health devices and telemedicine equipment have a rapidly growing market demand — monitor PPB regulatory developments for digital health/SaMD
  • For East African regional rollout: Kenya → Uganda (NDDA) → Tanzania (TMDA) → Rwanda (RDB) is the recommended sequence for regional sequential registration

Impact of Existing CE / FDA / NMPA Certificates

Quick Assessment

EU CE (MDR/MDD/IVDR)

• Recognition Mechanism: PPB (Pharmacy and Poisons Board) accepts EU CE certificates as the primary source of technical documentation proof in product registration applications. In PPB's technical review phase, products holding CE certificates are regarded as having undergone internationally recognized technical validation; the review committee correspondingly reduces the depth of independent safety and efficacy verification and the frequency of technical queries. PPB follows the GHTF framework and has high acceptance of Technical Files based on EU technical standards (ISO, IEC) — CE certificates effectively simplify the technical file requirements (especially the Clinical Evaluation Report component for Class C/D devices).
• Actual Effect: Products with CE certificates typically reduce technical supplementary information by 1–2 rounds in PPB reviews, shortening the overall review period by approximately 3–6 months. For an East Africa regional sequential registration strategy, Kenya PPB's accepting attitude toward CE is similarly referenced by Uganda (NDDA), Tanzania (TMDA), and Rwanda (RDB) — products registered in Kenya with CE certificates, when advancing registration in East African neighboring countries, find CE certificates having a positive effect in each country's review, creating regional synergy.
• Key Caveats: CE certificates must be within their validity period and from an EU-recognized Notified Body; if KEBS (Kenya Bureau of Standards) Conformity Assessment is also required, KEBS has high acceptance of CE certification EMC/electrical safety test reports, which can reduce additional testing requirements; Arabic/Swahili labeling is not mandatory but adding Swahili to retail packaging is recommended; English labeling is fully compliant for healthcare institution and B2B channels.

US FDA (510(k) / De Novo / PMA)

• Recognition Mechanism: FDA 510(k)/PMA approval is more recognized than CE in PPB evaluation — it is the single foreign certificate with the most positive influence on PPB review among all foreign certificates. PPB's Technical Committee has a high degree of recognition for FDA review standards; FDA approval is viewed as proof that the product has achieved the highest international technical standard. Additionally, holding FDA approval is of particularly important value for entering the KEMSA (Kenya Medical Supplies Authority) public procurement system and international agency procurement channels (UNICEF, UNDP, Clinton Health Access Initiative / CHAI) — these procurement entities explicitly prioritize FDA-approved (or WHO PQ) products in technical evaluations.
• Actual Effect: Products with FDA approval typically enjoy the smoothest review experience in PPB evaluation with the lowest probability of supplementary information requests; for Class C/D high-risk devices, FDA + CE dual certificates are the optimal configuration for entering the Kenyan market, simultaneously maximizing advantages at both the review and commercial levels. For entry into the KEMSA procurement list, FDA approval or WHO PQ certification is the most highly valued technical endorsement by procurement committees.
• Key Caveats: FDA documents must be currently valid; for entry into international agency procurement channels (UNICEF, etc.), certain product categories (IVDs, essential medicine-related devices) still require WHO PQ in addition — FDA approval supports but cannot replace WHO PQ applications; PPB Import Permits must be applied for separately from PPB registration certificates, with each batch of imports requiring individual processing — this requirement is independent of which foreign certificates are held.

China NMPA (National Medical Products Administration)

• Recognition Mechanism: PPB does not list China's NMPA as a reference regulatory authority. China-Kenya relations are friendly, with relatively active infrastructure and trade cooperation under the Belt and Road framework, and some Chinese medical aid projects (hospital construction, equipment donations) are active in Kenya; however, these fall under government-to-government bilateral aid frameworks and are entirely independent of PPB's commercial registration process — NMPA certificates do not carry formal exemption effect in routine PPB reviews.
• Actual Effect: No formal acceleration effect. Chinese manufacturers must provide the same complete registration documents as any other foreign manufacturer. NMPA certificates may be submitted as "approved by Chinese regulatory authorities" informational attachments — PPB reviewers will not treat them as a basis for reducing technical review requirements. For KEMSA public procurement and international agency procurement channels, NMPA certificates carry no competitive value; CE or FDA certificates must be used instead.
• Key Caveats: Chinese manufacturers entering Kenya must first obtain EU CE certification, then use the CE certificate to advance PPB registration; eligible products (IVDs, essential medical devices, etc.) should apply for WHO PQ to access KEMSA and international agency procurement channels; Chinese manufacturers' competitive advantage in Kenya primarily comes from price and product suitability — a complete international certification framework is required to enter formal procurement channels.

Practical Recommendations

1. CE is the core lever for East Africa regional registration: Using Kenya as the East Africa entry market, CE certificates have a positive effect in Kenya PPB, Uganda NDDA, Tanzania TMDA, and Rwanda RDB — creating "one certificate, multiple markets" regional synergy value; when advancing multi-country registration in East Africa, use CE technical files as a unified foundation and adapt to each country's local requirements
2. FDA is the key endorsement for public market and international agency procurement: Kenya's public healthcare market (KEMSA procurement) and international agency procurement in Kenya (UNICEF, UNDP, CHAI) place far greater importance on FDA approval or WHO PQ than on PPB registration certificates alone — manufacturers should treat FDA approval as a strategic investment for entering Kenya's high-value public market channels
3. KEBS compliance must be independently planned: Some products must additionally pass KEBS (Kenya Bureau of Standards) Conformity Assessment — this is a requirement independent of PPB registration. CE certification technical files (especially EMC and electrical safety test reports) can typically directly support KEBS evaluation, substantially reducing repetitive testing costs
4. WHO PQ as a medium-to-long-term strategic goal: For product categories suitable for WHO PQ (IVDs, essential medical equipment, reproductive health devices, etc.), WHO PQ certification is the highest-level pass for the entire international agency procurement ecosystem in Kenya and East Africa — manufacturers with FDA foundations should simultaneously assess the feasibility of WHO PQ applications
5. Monitor PPB new rules for digital health devices: Kenya is the most active market for digital health innovation in East Africa; PPB's regulatory rules for SaMD (Software as a Medical Device) and telemedicine devices continue to be updated — CE MDR software compliance documentation (software lifecycle documentation, cybersecurity requirements, etc.) carries important reference value in PPB reviews

Official Sources

• Pharmacy and Poisons Board (PPB): https://www.ppb.go.ke
• PPB Registration & Marketing Authorisation: https://ppb.go.ke/regulatory-functions/registration-marketing-authorisation
• PPB Guidelines for Registration of Medical Devices including In-Vitro Diagnostics (HPT/PER/HTR/GUD/011): https://ppb.go.ke/storage/v1/object/public/ppb-files/downloads/1784107129638-HPTPERHTPGUD011-Guideline-for-registration-of-MDs.pdf
• PPB regulatory notice on query response timelines and review cycles (25 September 2026): https://ppb.go.ke/storage/v1/object/public/ppb-files/downloads/1790410674131-REGULATORY-NOTICE--QUERY-RESPONSE-TIMELINES-AND-REVIEW-CYCLES-FOR-NEW-AND-RENEWAL-MARKETING-AUTHORISATION-APPLICATIONS.pdf
• Pharmacy and Poisons Act (Cap. 244), Kenya Law: https://new.kenyalaw.org/akn/ke/act/1956/17
• Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, Legal Notice No. 100 of 2022, Kenya Law: https://new.kenyalaw.org/akn/ke/act/ln/2022/100